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A B ST R AC T 
 
 
The intestinal microbiota represents an interesting and emergent field of 
research, with already known implications in metabolic and immunological 
functions. Recently, there is increasing evidence that specific gut microbial 
populations are associated with cardiovascular diseases. Numerous 
completed and ongoing studies aim to evaluate the potential of intestinal 
microbiota assessment to improve the prevention, diagnosis, and therapeutic 
arsenal of cardiovascular diseases, considering dysbiosis as a cardiovascular 
risk factor. There is strong evidence for a correlation between intestinal flora 
imbalance and metabolic changes secondary to bacterial metabolites. In this 
minireview, we discuss recent data about the connections between intestinal 
microbiota and cardiovascular disease.   
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Microbial cells are an important part of the human 
body, surpassing the number of normal cells [1]. Recent 
findings have shown that microbiota is responsible for 
multiple metabolic effects, interfering with body functions 
and creating the predisposition for specific diseases. Thus, 
in 2007, the Human Microbiome Project was launched by 
the United States National Institutes of Health to 
characterize the microbiota and microbe genomics, its role 
in human physiology and diseases’ pathogenesis, opening 
the door to developing innovative methods to alter 
microbial flora [2]. However, identification of certain 
microbial species in some particular diseases does not 
necessarily demonstrate an etiological relationship with 
individual health state or specific diseases. Furthermore, 
the project focused on microbial genomics, protein and 
metabolite production, and metabolism shifts, based on 
three longitudinal studies that had evaluated the role of gut 
microbiota in viral respiratory infections [2].  
Studies have demonstrated that changes in gut 
microbiota composition over the years can interfere with 
aging processes such as muscular atrophy or a decrease of 
innate immunity and cognitive impairment, opening the 
opportunity to investigate the relationship of microbiota 
phenotypes and frailty [3]. The presence of a microbial 
population is vital for the human body physiology. 
However, it was demonstrated that a scarce exposure of the 
human body to bacterial organisms or antibiotic treatments 
is implicated in inflammatory dysregulation, linked to 
metabolic disorders and even to malignant diseases [4-6]. 
Thus, the current efforts have focused on research for 
modalities to repopulate the microbial flora, which proved 
to be efficient in trials, with emerging indications of 
probiotic bacteria as therapeutic intervention [4-6]. 
The normal gut microbiota is mainly formed by 
anaerobic organisms, such as Firmicutes and 
Bacterioidetes, the dominant families, and also 
Fusobacteria, Proteobacteria, Actinobacteria, 
Verrucomicrobia etc. The symbiotic relationship between 
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the host and the gut flora represents an important condition 
for human evolution. An optimal environment for bacterial 
growth is necessary for nutrient absorption and intestinal 
barrier, stimulating also the immune system [4]. 
Some bacterial organisms, such as Lactobacillus 
strains, induce the production of reactive oxygen species 
into the intestinal cells, which enter into the redox cascade 
signaling pathways modulation, stimulating cytoprotective 
genes, with cellular proliferation and differentiation, hence 
maintaining the integrity and function of the epithelium 
[7].  
Intestinal bacteria digest the nutrients that the human 
body is unable to, such as partially and non-digestible 
polysaccharides (starch and fibers), releasing short fatty 
chain acids which are absorbed and involved in signaling 
pathways, metabolism regulation, and the release of satiety 
hormones (peptide YY, glucagon-like peptide-1) [8]. One 
significant metabolite is acetate, which demonstrated in 
murine experiments a decrease of total body fat as 
compared to a control group [9]. In human subjects, acetate 
reduced the circulating levels of free fatty acids by 
decreasing the lipolysis mechanism and improving insulin 
sensitivity [10]. Butyrate, another bacteria metabolite, has 
shown a reduction of insulin resistance and body weight in 
obese mice [11].  
The bacterial metabolites also demonstrated an 
unexpected effect on the immunological response, by 
mediating the T-cell differentiation into T-cells that 
produce interleukin 17, interferon-gamma or interleukin-
10 through a direct effect on histone enzyme activity, 
changing the conformation of the DNA-histone complex 
and gene expression [12]. The short-chain fatty acids 
decreased the pro-inflammatory response, measured by 
serum cytokines levels (tumor necrosis alpha) after four 
weeks of prebiotic and probiotic supplementation [13]. In 
experimental studies, butyrate decreased the activity of T 
helper 1 cells and interleukin 2 production, thus explaining 
the beneficial effects in patients with inflammatory bowel 
disease [14]. Mainly, the short-chain fatty acids selectively 
promote immunological tolerance, with an increase of 
regulating T lymphocytes and decrease of effector T cells 
[15], influencing even the immune response to other 
bacterial antigens such as lipopolysaccharide [16]. 
The commensal bacterial populations survive in niches, 
producing antimicrobial factors that prevent an invading 
pathogen to multiply. They ensure that neither one of the 
populations out-compete the other, and preserve the 
balance. Besides reactive oxygen species and short-chain 
fatty acids that are locally produced, bacteria generate 
bacteriocins, which are antimicrobial peptides released 
extracellular [17]. The Bifidobacterium strains, for 
example, produce bacteriocin against Clostridium difficile 
and Escherichia coli, to ensure competition [18]. 
Discussions 
Gut microbiota and atherosclerosis 
Atherosclerosis represents a cardiovascular risk factor, 
the result of multiple concurring causes. It is responsible 
not only for coronary artery disease but also for stroke, 
peripheral artery disease, etc. Atherosclerosis is 
responsible for the majority of acute coronary syndromes 
(over 80% of non-ST-segment elevation myocardial 
infarction, according to the European Society of 
Cardiology Guidelines) [19]. 
The microorganisms have been implicated in 
atherosclerosis since late 1880. Infection with Chlamydia 
pneumoniae, an intracellular bacterium, induces the 
transformation of macrophages into foam cells, with 
leukocyte recruitment, inflammation, and smooth muscular 
fiber proliferation, leading to atherosclerotic changes in the 
vascular wall [20]. Porphyromonas gingivalis, a gram-
negative, anaerobic Bacteroidetes species, is implicated in 
periodontal disease and colonic colonization, but it has also 
been isolated from atherosclerotic lesions in animal models 
[20]. Intestinal presence of Veillonellaceae species, as part 
of Firmicutes phylum, has been associated with elevated 
circulating vascular cell adhesion molecule 1 (VCAM-1) 
in obese children [21]. Elevated circulating levels of 
VCAM-1 are correlated with subclinical atherosclerosis 
and are implicated in monocyte recruitment, hence 
demonstrating its role in diagnosis and secondary 
prevention [22]. 
In murine experiments with apolipoprotein E-deficient 
knock-out mice predisposed to atherosclerosis, the germ-
free group presented increased atherosclerotic plaques 
compared to mice with a conventional microbiota, even 
when fed with low-lipid diet. This study strengthened the 
previous conclusion that commensal flora has a protective 
role in atherosclerosis [23]. 
Gut microbiota and inflammation 
Microbial products represent potential activators of the 
host immune system, especially lipopolysaccharides and 
peptidoglycans that bind to the toll-like receptors (TLR) 
and nucleotide-binding oligomerization domain [24]. 
However, not all subgroups of TLR are implicated in 
atherosclerosis. The absence of some TLRs, such as TLR 
2 and TLR 4, decreased the rate of lipid accumulation and 
monocyte chemotaxis in animal models [8]. 
In an experimental murine study, after one month of 
high-fat meals, an increase in circulating levels of 
lipopolysaccharides was correlated with an increase in 
insulin resistance and obesity. The result was similar in 
normal fed mice but with induced endotoxemia. Thus, 
chronic inflammation produced by bacterial metabolites 
represents a cornerstone in the pathophysiology of 
cardiovascular diseases and can explain why gut 
microbiota may be a cardiovascular risk factor [25]. 
Roua Iorga et al.  
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However, obesity itself is a cause of chronic inflammation, 
because of immune cells activated by metabolic stress, thus 
switching to pro-inflammatory cells, with an increase in 
lymphocytes and macrophages population [26] and 
alterations of adipocytes such as hypertrophy, ischemia, 
and adipocytokine production [27-29]. 
Gut microbiota and cardiovascular disease 
Bacterial metabolites are implicated in immune 
responses, as shown above, but butyrate and beta-
hydroxybutyrate were correlated with atherosclerosis 
inhibition, thus cardiovascular protection [20]. However, 
other bacterial metabolites, such as trimethylamine (TMA) 
and trimethylamine N-oxide (TMAO), have demonstrated 
a pro-atherogenic effect, with the strongest evidence of 
positive correlation with cardiovascular risk in a trial on 
4007 patients during 3 years of follow-up [30,31]. 
Recently, a cohort study demonstrated that the 
consumption of processed and unprocessed red meat is 
associated with an increased risk of cardiovascular disease 
and all-cause mortality [32]. The mechanism can be 
explained by the high levels of L-carnitine, 
phosphatidylcholine, and choline found in red meat, that 
increase the serum TMAO, hence inducing atherosclerosis 
by the accumulation of macrophages, alteration of the 
reverse cholesterol transport, and increase of thrombocytes 
activity [30,33]. The incriminated bacteria may belong to 
the Clostridiaceae and Peptostreptococcaeae families 
[30,34]. However, some molecules counteract the effects 
of TMA and TMAO production, even in a high-choline 
diet, such as dimethyl-butanol found in olive oil, grape-
seed oil, and red wine [35]. 
The imbalance of commensal flora, with a 
predominance of the phylum Firmicutes over 
Bacteroidetes, was associated with obesity [35]. An 
increased count of Lactobacillus strains (belonging to the 
phylum Firmicutes) was found in diabetic patients [30,36], 
although the reasons are unclear. Consistently, the phylum 
Bacteroidetes was present at low levels in diabetic patients 
[30]. 
Gut microbiota and heart failure 
Heart failure is the final stage of evolution of the 
majority of cardiovascular diseases, such as coronary 
artery disease, arterial hypertension, etc. Recent studies 
have evaluated microbiota involvement in heart failure and 
demonstrated an increase in species like Campylobacter, 
Shigella, and Candida [36,37]. Intestinal congestion 
encountered in heart failure is responsible for the intestinal 
epithelial alteration, with secondary bacterial translocation 
and persistent endotoxemia that contribute to chronic 
inflammation and disease worsening [38,39]. Bacterial 
translocation has been associated with an inflammatory 
syndrome and an increase of circulating levels of C-
reactive protein and interleukin 6 [40-42]. 
Gut microbiota and arterial hypertension 
Consistent with the findings described above, patients 
with arterial hypertension have increased phylum 
Firmicutes to Bacteroidetes ratio. Also, short-chain fatty 
acids have been associated with an increase of 
Bacteroidetes population in mice and a decrease in blood 
pressure values, due mainly to the direct stimulation of 
receptors in renal arteries [43-45]. 
Conclusions 
Gut microbiota and its involvement in cardiovascular 
diseases represent an emerging field of research that may 
offer attractive therapeutic options to a large category of 
patients. The changes in the gut microbiota population are 
highly correlated with cardiovascular diseases, obesity, 
diabetes mellitus, and even malignant diseases. The 
characterization of the microbiota genome and isolation of 
their metabolites are important steps forward to create new 
methods of prevention, diagnosis, and improvement of the 
therapeutic interventions. Lifestyle changes, higher food 
quality, avoidance of unnecessary antibiotic treatment, and 
use of pre- and probiotics are universal preventive 
measures. 
Highlights 
✓ Recent findings have shown that microbiota is 
responsible for multiple metabolic effects, interfering 
with body functions and creating the predisposition for 
specific diseases. 
✓ There is increasing evidence that specific gut 
microbial populations are associated with 
cardiovascular diseases. 
✓ The characterization of the microbiota genome and 
isolation of their metabolites are important steps 
forward to create new methods of prevention, 
diagnosis, and improvement of therapeutic 
interventions. 
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